ArticleCells2026
Metabolic Reprogramming of the Liver by IL-33: A Protective Response to Acute Injury.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
aimsThe glucose metabolism pattern of the liver is closely related to liver diseases. In recent years, alcoholic hepatitis, viral hepatitis, fatty liver and other diseases have become important liver diseases that impact people's lives. IL-33 (interleukin-33), as a member of the IL-1 cytokine family, and "alarmin" play a multi-dimensional regulatory role in various physiological and pathological processes of the liver.
methodsThis study, by integrating transcriptomic data analysis and in vitro and in vivo experiments, expounds on new insights into the regulation of hepatocyte fate by IL-33 through metabolic reprogramming and reveals the potential, new role of IL-33 as a regulatory factor of metabolism.
conclusionsOur research further confirmed that IL-33, in addition to serving as an alarm hormone, is also a key checkpoint for liver metabolism, capable of promoting oxidative phosphorylation in hepatocytes and antagonizing acute liver injury induced by CCl
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.